Abstract
Patients with lysosomal storage diseases may require modifications to standard drug desensitization protocols; personalized medicine as well as development of new treatment options are needed.
Copyright © 2022 by the American Academy of Pediatrics.
MeSH terms
-
Anti-Allergic Agents / therapeutic use
-
Chondroitinsulfatases / administration & dosage*
-
Chondroitinsulfatases / blood
-
Chondroitinsulfatases / immunology*
-
Female
-
Humans
-
Mucopolysaccharidosis IV / blood
-
Mucopolysaccharidosis IV / drug therapy*
-
Mucopolysaccharidosis IV / immunology*
-
Omalizumab / therapeutic use
-
Rhinitis, Allergic / blood
-
Rhinitis, Allergic / drug therapy
-
Rhinitis, Allergic / immunology
-
Treatment Outcome
-
Young Adult
Substances
-
Anti-Allergic Agents
-
Omalizumab
-
Chondroitinsulfatases
-
GALNS protein, human